HealthExec December 11, 2024
Dave Fornell

The critical gap in AI post-market validation

Califf stressed that the biggest concern lies in the post-market phase of AI deployment. Unlike traditional medical devices, AI systems can evolve as they interact with new data, leading to either improved or degraded performance. Without continuous validation, health systems risk relying on algorithms that no longer provide accurate or reliable results.

“It’s clear that particularly with generative AI, you put it in place and then it changes,” he said. “The big deal in AI isn’t the pre-market phase, it’s the post-market phase. You need to continuously validate the model in the environment in which you’re using it. And unfortunately, there’s not a single health system in the U.S. that can do that...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: AI (Artificial Intelligence), FDA, Govt Agencies, Health System / Hospital, Provider, Technology
Supporting the Development of Drugs for Rare Diseases — The Importance of Regulatory Transparency
Opinion: To fight for those with rare diseases, Trump must reform and modernize the FDA thoughtfully
5 Rare Diseases That Now Have Their First FDA-Approved Treatments
This Bill Could Make It Legal for AI to Prescribe Medicine
STAT+: Trump’s FDA navigates layoffs, exits, and a new hire

Share This Article